With insitro deal, Gilead turns to machine learning to unlock new NASH targets

Not yet content with the trio of clinical programs in its pipeline, Gilead has struck its third NASH deal this year, this time banking on machine learning company insitro to develop disease models and discover targets for non-alcoholic steatohepatitis.

Making its first biopharma deal since launching last year,

Read the full 473 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers